We are delighted to announce a new strategic partnership with Nano4Imaging, the German medical device company specializing in interventional MRI products. Arrotek’s leading manufacturing facility in Boston, USA will take over final manufacturing of Nano4Imaging’s MR Wire guide-wire, also known as the EmeryGlide guide-wire.
The MR Wire guide-wire is an MRI-compatible guide-wire with FDA clearance as an MR conditional product. It is made with a core comprised of a high-strength composite of glass fibers and polymers with an aramid fiber mantle that is covered with a PTFE extrusion.
As it is an MR conditional product, the MR Wire guide-wire offers an alternative for diagnosing and monitoring heart conditions where routine methods often involve the use of CT scans that expose patients to radiation. The guide-wire also offers procedural benefits as the heart can be seen directly under an MRI scan without the need for contrast media.
Strategic Partnership
The strategic partnership with Arrotek enables Nano4Imaging to significantly expand its production capabilities in the United States. In addition to manufacturing, our team will also handle logistics. Our design team will also be working with Nano4Imaging on the design of other composite components and MRI-compatible medical devices.
Keith Spodek is Site Leader and VP of Operations at Arrotek in the United States. He welcomed the new partnership: “We are confident that our working relationship presents significant opportunities for both parties by expanding Nano4Imaging’s interventional MRI portfolio with advanced products such as needles.”
Rudolf Schulze Vohren, CEO of Nano4Imaging, said: “This collaboration brings us closer to our U.S. customers at a critical time when there is a significant shortage of MRI-compatible medical devices. Partnering with Arrotek enables us to address this gap effectively, positioning us as a leader in the fast-growing interventional MRI market, which is expected to expand at a compound annual growth rate of 24%, reaching $2.3 billion in the next five years.”
